ACTION WARNING TO SHAREHOLDERS: Schall regulation agency publicizes class motion lawsuit has been filed towards MEI Pharma, Inc. and encourages buyers with losses in extra of $ 100,000 to achieve out to the regulation agency – Enterprise Wire
LOS ANGELES–(BUSINESS WIRE) – Schall law firm, a national shareholder law firm, has announced it has filed a class action lawsuit against MEI Pharma, Inc. ("MEI Pharma" or "the Company") (NASDAQ: MEIP) for §§ violations. 10 (b) and 20 (a) of the Securities Exchange Act of 1934 and Rule 10b-5, published by the US Securities and Exchange Commission.
Investors who purchased the Company's securities between August 2, 2017 and July 1, 2020 (including the “Class Period”) are encouraged to contact the Company before October 9, 2020.
If you are a shareholder who has suffered a loss, click here to participate.
We also recommend that you contact Brian Schall of the Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335 to discuss your rights free of charge. You can also contact us on the company's website at www.schallfirm.com or by email at email@example.com.
In this case, the class has not yet been certified and you will not be represented by a lawyer until certification. If you take no action, you can remain an absent class member.
According to the complaint, the company made false and misleading statements about the market. MEI Pharma has overestimated the potential effectiveness of its drug pracinostat for the treatment of acute myeloid leukemia ("AML") in its target population. It was therefore unlikely that the phase 3 study of pracinostat would meet its primary endpoint for overall survival. Based on these facts, the company's public statements throughout the teaching period were incorrect and essentially misleading. When the market learned the truth about MEI Pharma, investors suffered damage.
Join the case to make up for your losses.
The law firm Schall represents investors all over the world and specializes in class actions and shareholder litigation.
This press release may be viewed as a solicitation in some jurisdictions under applicable laws and ethical rules.